Loading…
Aarti Pharmalabs (AARTIPHARM)₹921.40−0.89%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Aarti Pharmalabs reported sales of ₹609 Cr, up 46.0% from Sep 2025, and net profit of ₹71.20 Cr, up 153.8% year on year. For the year to Mar 2026, sales were ₹1,816 Cr and net profit ₹175 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 448 | 505 | 554 | 457 | 537 | 563 | 385 | 417 | 431 | 582 | 535 | 609 |
| Expenses | 352 | 387 | 458 | 363 | 408 | 417 | 293 | 343 | 329 | 469 | 399 | 474 |
| Operating Profit | 95.73 | 118 | 95.81 | 93.81 | 129 | 146 | 92.74 | 73.81 | 102 | 113 | 136 | 135 |
| OPM % | 21.0% | 23.0% | 17.0% | 20.0% | 24.1% | 26.0% | 24.0% | 18.0% | 24.0% | 19.0% | 25.0% | 22.0% |
| Other Income | 1.01 | 2.01 | 2.01 | 4.01 | 5.01 | −2.01 | 2.01 | 0.00 | 2.01 | 14.02 | 8.01 | 5.01 |
| Interest | 3.98 | 4.98 | 4.98 | 5.98 | 9.97 | 6.98 | 6.97 | 10.96 | 12.97 | 16.95 | 12.97 | 14.95 |
| Depreciation | 19.01 | 19.02 | 20.01 | 21.01 | 23.01 | 23.02 | 23.02 | 25.01 | 29.01 | 28.04 | 30.04 | 31.02 |
| Profit before tax | 74.02 | 96.14 | 74.07 | 72.11 | 101 | 115 | 65.08 | 39.05 | 63.03 | 82.03 | 101 | 95.07 |
| Tax % | 28.9% | 31.9% | 24.9% | 23.9% | 25.9% | 22.9% | 23.9% | 27.9% | 23.9% | 24.9% | 24.9% | 24.9% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −2.01 | 0.00 | 0.00 | −2.01 |
| Net Profit | 53.07 | 65.13 | 55.14 | 55.08 | 74.14 | 88.21 | 50.09 | 28.05 | 48.08 | 61.10 | 76.17 | 71.20 |
| EPS (Rs) | 5.84 | 7.23 | 6.14 | 6.05 | 8.19 | 9.79 | 5.48 | 3.09 | 5.31 | 6.77 | 8.42 | 7.91 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales | 1,198 | 1,941 | 1,848 | 2,113 | 1,816 | 2,158 |
| Expenses | 992 | 1,600 | 1,465 | 1,647 | 1,447 | 1,672 |
| Operating Profit | 207 | 341 | 385 | 465 | 368 | 485 |
| OPM % | 17.0% | 18.0% | 21.0% | 22.0% | 20.0% | 22.5% |
| Other Income | 3.01 | 2.01 | 5.01 | 8.01 | 15.02 | 29.05 |
| Interest | 11.95 | 20.91 | 16.95 | 26.91 | 46.86 | 57.84 |
| Depreciation | 42.03 | 63.04 | 73.09 | 87.08 | 104 | 118 |
| Profit before tax | 155 | 261 | 300 | 362 | 233 | 341 |
| Tax % | 20.9% | 25.9% | 27.9% | 23.9% | 24.9% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | −2.01 | −4.02 |
| Net Profit | 122 | 193 | 217 | 273 | 175 | 257 |
| EPS (Rs) | — | 21.43 | 24.03 | 30.18 | 19.34 | 28.41 |
| Dividend payout % | 0.0% | 9.0% | 12.9% | 16.9% | 17.9% | — |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.24 | 44.99 | 44.99 | 45.01 | 45.03 |
| Reserves | 0.00 | 1,386 | 1,513 | 1,713 | 1,943 | 2,078 |
| Borrowings | 0.00 | 337 | 215 | 284 | 413 | 753 |
| Other Liabilities | 0.00 | 313 | 469 | 537 | 498 | 602 |
| Total Liabilities | 0.00 | 2,038 | 2,242 | 2,580 | 2,899 | 3,479 |
| Fixed Assets | 0.00 | 782 | 925 | 1,033 | 1,136 | 1,436 |
| CWIP | 0.00 | 186 | 102 | 137 | 373 | 392 |
| Investments | 0.00 | 32.09 | 87.22 | 107 | 77.26 | 195 |
| Other Assets | 0.00 | 1,037 | 1,129 | 1,303 | 1,314 | 1,456 |
| Inventories | 0.00 | 475 | 601 | 642 | 587 | 639 |
| Trade receivables | 0.00 | 377 | 449 | 519 | 575 | 583 |
| Cash & equivalents | 0.00 | 82.67 | 11.96 | 23.91 | 8.96 | 9.96 |
| Total Assets | 0.00 | 2,038 | 2,242 | 2,580 | 2,899 | 3,479 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | −43.94 | 249 | 216 | 330 | 262 |
| Cash from investing activity | −139 | −158 | −216 | −413 | −432 |
| Cash from financing activity | 261 | −164 | 10.02 | 65.17 | 172 |
| Net cash flow | 77.84 | −70.87 | 11.98 | −16.96 | 1.99 |
| Capex | 141 | 120 | 200 | 445 | 449 |
| Free cash flow | −185 | 130 | 18.03 | −114 | −186 |
| CFO / OP % | −10.9% | 91.1% | 71.1% | 85.1% | 84.1% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 115 | 84 | 102 | 99 | 117 |
| Inventory days | 272 | 188 | 230 | 199 | 280 |
| Days payable | 123 | 106 | 135 | 94 | 146 |
| Cash conversion cycle | 264 | 166 | 197 | 204 | 251 |
| Working capital days | 111 | 94 | 110 | 105 | 90 |
| ROCE % | 19.1% | 16.1% | 17.1% | 17.1% | 11.1% |
For the Sep 2026 quarter, Aarti Pharmalabs reported sales of ₹609 Cr, up 46.0% year on year and net profit of ₹71.20 Cr, up 153.8% year on year. The operating margin was 22.0%.
Aarti Pharmalabs' sales for the year to Mar 2026 were ₹1,816 Cr; over the last twelve months they were ₹2,158 Cr.
Net profit for the year to Mar 2026 was ₹175 Cr, and ₹257 Cr over the last twelve months. Earnings per share over the same trailing period were ₹28.41.
Aarti Pharmalabs reported borrowings of ₹753 Cr at Mar 2026, against cash and equivalents of ₹9.96 Cr.
Cash from operations was ₹262 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹186 Cr.